Telomir Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures Power of Attorney (included on signature page)
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TELOMIR PHARMACEUTICALS, INC. | ||
| Date: March 17, 2026 | By: | /s/ Erez Aminov |
|---|---|---|
| Erez Aminov | ||
| Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| By: | /s/ Alan Weichselbaum | |
| Alan Weichselbaum | ||
| Chief Financial Officer | ||
| (Principal Financial Officer) | ||
In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Person | Capacity | Date |
|---|---|---|
| /s/ Erez Aminov | Chief Executive Officer and Chair | March 17, 2026 |
| Erez Aminov | (Principal Executive Officer) | |
| /s/ Alan Weichselbaum | Chief Financial Officer | March 17, 2026 |
| Alan Weichselbaum | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Ned MacPherson | Director | March 17, 2026 |
| Ned MacPherson. | ||
| /s/ Matthew Pratt Whalen, CPA | Director | March 17, 2026 |
| Matthew Pratt Whalen, CPA | ||
| /s/ Matthew P. Del Giudice | Director | March 17, 2026 |
| Matthew P. Del Giudice | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.